The Zenas BioPharma, Inc. (Nasdaq: ZBIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zenas is a clinical-stage global biopharmaceutical company focused on therapies for autoimmune diseases, and its filings document key aspects of its business, including stock exchange listing details, financing arrangements, licensing agreements and clinical development updates.
Recent Form 8-K filings describe material events such as the revenue participation and funding agreement with Royalty Pharma related to obexelimab, under which Royalty Pharma will provide up to $300 million in consideration in exchange for specified royalty and revenue participation rights. Other 8-Ks detail the license agreement with InnoCare Pharma granting Zenas exclusive rights to develop, manufacture and commercialize orelabrutinib in the multiple sclerosis field globally and non-oncology indications outside certain territories, as well as rights to ZB021 and ZB022. Additional current reports cover private placement financings, adoption of the 2026 Inducement Plan for equity awards, and press releases furnishing quarterly financial results.
Through this page, users can review how Zenas reports its status as an emerging growth company, its listing of common stock on The Nasdaq Global Select Market under the symbol ZBIO, and the terms of material definitive agreements that shape its capital structure and pipeline strategy. Filings linked here include exhibits such as inducement equity plans, option and restricted stock unit agreements, subscription and registration rights agreements, and revenue participation contracts, which provide further detail on governance and compensation frameworks.
Stock Titan enhances these documents with AI-powered summaries that explain the significance of each filing in clear language. As new 8-Ks, 10-Qs, 10-Ks and other forms become available on EDGAR, they are incorporated so investors can quickly see how developments in obexelimab, orelabrutinib, ZB021 and ZB022, as well as financing and licensing transactions, are reflected in Zenas BioPharma’s official regulatory record.
Zenas BioPharma, Inc. reported that officer Lisa von Moltke received a grant of stock options covering 150,000 shares of common stock. The options have an exercise price of $18.71 per share and expire on June 15, 2036.
The grant vests as to 25% of the underlying shares on June 15, 2027, the first anniversary of the vesting commencement date. The remaining 75% vests in equal monthly installments over the following 36 months, subject to her continued service. Following this award, she holds 150,000 stock options directly.
Zenas BioPharma, Inc. reported that director Patricia L. Allen received a grant of stock options covering 18,500 shares of common stock. The options have an exercise price of $18.71 per share and expire on June 15, 2036. They vest in full on June 15, 2027, subject to continued service.
Zenas BioPharma, Inc. reported a Form 4 showing director James P. Boylan received a grant of stock options covering 18,500 shares of common stock at an exercise price of $18.71 per share. These options were awarded as compensation rather than through an open-market purchase.
The option vests as to 100% of the underlying 18,500 shares on June 15, 2027, subject to Boylan’s continued service. The options expire on June 15, 2036, providing a long exercise window. The filing notes Boylan holds the option for the benefit of Enavate Sciences, L.P. and disclaims beneficial ownership except for any pecuniary interest. Following this grant, 18,500 derivative securities are reported as held directly.
Zenas BioPharma, Inc. director Patrick G. Enright reported receiving a grant of stock options covering 18,500 shares of common stock at an exercise price of $18.71 per share. The options were awarded as compensation and are held directly.
The option vests as to 100% of the 18,500 underlying shares on June 15, 2027, subject to his continued service, and expires on June 15, 2036. No open-market purchase or sale of Zenas BioPharma common stock was reported in this filing.
Zenas BioPharma, Inc. reported that officer Joseph L. Farmer received equity-based compensation. He was granted stock options for 175,000 shares of common stock at an exercise price of $18.71 per share, expiring on June 15, 2036, and acquired 974 shares of common stock through the 2024 Employee Stock Purchase Plan at $13.35 per share.
Zenas BioPharma, Inc. reported that officer Jennifer A. Fox received equity awards in the form of an option grant and common shares. On June 15, 2026, she was granted 125,000 stock options to buy common stock at $18.71 per share, expiring on June 15, 2036. The option vests 25% on June 15, 2027, then in equal monthly installments over the following 36 months, subject to continued service. On February 5, 2026, she also acquired 1,592 common shares at $13.35 under the company’s 2024 Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(c).
Zenas BioPharma, Inc. Chief Executive Officer Leon O. Moulder Jr. reported an open-market purchase of 60,000 shares of Common Stock. The shares were bought indirectly through an entity associated with him at a weighted average price of $16.88 per share, with individual trade prices ranging from $16.59 to $16.97. After this transaction, that indirect account held 96,928 shares. As of the same date, he also reported 423,155 shares held directly and 1,786,039 additional shares held indirectly through entities where he may be deemed to have voting and dispositive power, while disclaiming beneficial ownership beyond his pecuniary interest.
Zenas BioPharma, Inc. reported a larger quarterly loss as it ramped up immunology pipeline development while significantly strengthening its balance sheet.
For the three months ended March 31, 2026, the company generated no revenue compared with $10.0 million a year earlier from a prior license payment. Research and development expenses rose to $60.4 million and general and administrative expenses to $16.9 million, driving a net loss of $81.0 million, or $1.46 per share, versus a $33.6 million loss in the prior-year quarter.
Zenas ended the period with $718.5 million in cash, cash equivalents and investments, up from $360.5 million at year-end 2025. The increase reflects net operating cash use of $75.2 million offset by substantial financing activity, including a new $75.0 million senior secured term loan, issuance of $200.0 million of 2.50% convertible senior notes due 2032, a follow-on equity offering of 5,000,000 shares and at-the-market share sales. The company also carries an $84.9 million royalty obligation related to its obexelimab program. Management expects existing liquidity to fund operating and capital needs for at least twelve months from issuance of these financial statements while it advances obexelimab and other autoimmune candidates through clinical development.
Zenas BioPharma, Inc. reported first quarter 2026 results showing no revenue versus $10.0 million a year earlier and a higher net loss of $80.99 million, or $1.46 per share, compared with a $33.57 million loss, or $0.80 per share, in 2025. Operating expenses rose sharply, led by research and development spending of $60.44 million. Cash, cash equivalents and investments increased to $718.55 million as of March 31, 2026, from $360.46 million, after completed public offerings and new debt financing, which the company says extends its cash runway into 2029. Total liabilities increased to $411.85 million, including royalty obligations, a senior secured term loan and convertible senior notes.
Zenas highlighted progress in its autoimmune pipeline, including Phase 3 INDIGO results for obexelimab in IgG4‑Related Disease, ongoing Phase 3 multiple sclerosis trials for orelabrutinib, and Phase 1 development of oral IL‑17 inhibitor ZB021. At its 2026 Annual Meeting, stockholders elected two Class II directors, ratified Ernst & Young LLP as auditor, and the board size was reduced by one following Tomas Kiselak’s previously announced departure.
Zenas BioPharma, Inc. insider Leon O. Moulder Jr. and related entities report beneficial ownership of 3,220,880 shares of common stock, representing 5.09% of the class. The stake includes 423,155 shares held directly, 974,758 shares underlying stock options exercisable within 60 days of April 29, 2026, 1,786,039 shares held by Tellus BioVentures, LLC, and 36,928 shares held by a revocable trust.
The filing details long‑running investments in the company’s predecessor, multiple preferred share and note financings, IPO‑related and subsequent option grants, PIPE participation, and open‑market purchases, including 271,000 shares bought between January 7 and April 29, 2026. The reporting persons describe the holdings as for general investment purposes but may increase or reduce their position over time. They also hold registration and piggyback rights under shareholder and PIPE registration rights agreements.